Use of beta-blockers in congestive heart failure

Annals of Medicine

Volumn 35, Issue 4, 2003, Pages 259-266

  Sallach, John A ^a,c   Goldstein, Sidney ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Henry Ford Heart/Vascular Institute   (United States)

^c HENRY FORD HOSPITAL   (United States)

Author keywords

Beta blockers; Congestive heart failure; Morbidity; Mortality

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CARVEDILOL; METOPROLOL;

BODY WEIGHT DISORDER; CARDIOGENIC SHOCK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FEMALE; FLUID RETENTION; HEART FAILURE; HEMODYNAMICS; HUMAN; HYPOTENSION; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; BISOPROLOL; CARBAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; FORECASTING; HEART FAILURE, CONGESTIVE; HUMANS; METOPROLOL; PROPANOLAMINES; RANDOMIZED CONTROLLED TRIALS;

EID: 0037713412     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.1080/14734220310011716     Document Type: Review

References (25)

1. Eichhorn EJ. Experience with Beta blockers in heart failure mortality trials. Clin Cardiol 1999; 22(Suppl. V): V21-9.
2. Heidenreich PA, Lee TT, Massie BM. Effect of Beta-blockade on mortality in patients with heart failure: A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997; 30: 27-34.
3. Goldstein S. Clinical studies on Beta blockers and heart failure preceding the MERIT-HF Trial. Am J Cardiol 1997; 80(9B): 50J-3.
4. Goldstein S, Gottlieb SS. The impact of Beta-blockade on mortality rates in patients with congestive heart failure. J Card Fail 2000; 6(2 Suppl 1): 15-24.
5. Thomas J, Marks BH. Plasma norepinephrine in congestive heart failure. Am J Cardiol 1978; 41: 233-43.
6. Cohn JN, Levine TB, Olivari MET, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819-23.
7. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of Carvedilol on morbidity and mortality in patients with chronic heart failure. The U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-55.
8. CIBIS-II Investigators and Committees. The cardiac insufficiency Bisoprolol study II (CIBIS-II): A randomised trial. Lancet 1999; 353: 9-13.
9. MERIT-HF Study Group. Effect of Metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999; 353: 2001-7.
10. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the Beta-blocker Bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344: 1659-67.
11. The Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of Carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-8.
12. Libby P, Warner SJ, Friedman GB. Interleukin 1; a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J Clin Invest 1988; 81: 487-98.
13. Gilbert EM, Olsen SL, Renlund DG, Bristow MR. Beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. Am J Cardiol 1993; 71: 23C-9.
14. Newton GE, Parker JD. β1 versus non-selective β-blockade in human congestive heart failure: Acute effects on cardiac sympathetic activity. Circulation 1995; 92: Suppl I: I-395 abstract.
15. Olsen S, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure. A double-blind randomized study. J Am Coll Cardiol 1995; 25: 1225-31.
16. Yue T-L, Cheng H-Y, Lysko PG, McKenna PJ, Feuerstein R, Gu JL, et al. Carvedilol, a new vasodilator and Beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992; 263: 92-8.
17. Bril A, Slivjak M, DiMartino MJ, Feuerstein GZ, Linee P, Poyser RA, et al. Cardioprotective effects of Carvedilol, a novel Beta adrenoceptor antagonist with vasodilating properties, in anaesthetized minipigs: comparison with propranolol. Cardiovasc Res 1992; 26: 518-25.
18. Dhalla AK, Singh N, Singal PK. Antioxidant therapy associated with the reversal of oxidative stress delays the pathogenesis of heart failure. Circulation 1994; 90: 1-491. abstract.
19. CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure: the cardiac insufficiency Bisoprolol study (CIBIS). Circulation 1994; 90: 1765-73.
20. Haeusler G, Schliep HF, Schelling P, Becker KH, Klockow M, Minck KO, et al. High β1-selectivity and favourable pharmacokinetics as the outstanding properties of Bisoprolol. J Cardiouasc Pharmacol 1986; 8(suppl II): S2-15.
21. Wagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, et al. for the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of Metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1441-6.
22. The Digitalis Investigaiton Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-33.
23. Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, et al. β-blockade with Bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991; 84: 2426-41.
24. Eichhorn EJ. Our new understanding of heart failure: The role of beta-blockers in treatment. Cleve Clin J Med 1998; 65: 428-35.
25. Carson PE. Beta-blocker treatment in heart failure. Prog Cardiovasc Dis 1999; 41: 301-22.